Timed walk as primary outcome measure of treatment response in clinical trials for HTVL-1-associated myelopathy

The journal Pilot and Feasibility Studies has published a study about the treatment of HTVL-1-associated myelopathy. To advance the treatment of HTVL-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), randomized controlled therapeutic studies with appropriate and sensitive outcome are reuired. Data on 10MWT from 76 patients with HAM/TSP were prospectively collected from four specialist centres in Brazil, Japan, USA and UK. Baseline mean (standard deviation= SD), median 10MWT were 23.5 (18.9), 16.3 s/ 10 m and at 6 months 24.9 (23.9), 16.4 s/ 10 m. The mean (SD) % increase in walk time was 5.74% (28.2%). The intra-patient variability of 10MWT is relatively small in HAM/TSP over 6 months. The full-text study you can find here.